WASHINGTON (dpa-AFX) - Nektar Therapeutics (NKTR) released Loss for third
quarter that decreased from the same period last year but beat the Street
estimates.

The company's bottom line came in at -$45.84 million, or -$0.24 per share. This compares with -$59.05 million, or -$0.31 per share, in last year's third
quarter.

Analysts on average had expected the company to earn -$0.20 per share, according
to figures compiled by Thomson Reuters. Analysts' estimates typically exclude
special items.

The company's revenue for the quarter rose 2.2% to $24.14 million from $23.63
million last year.

Nektar Therapeutics earnings at a glance (GAAP) :

-Earnings (Q3): -$45.84 Mln. vs. -$59.05 Mln. last year.
-EPS (Q3): -$0.24 vs. -$0.31 last year.
-Analyst Estimates: -$0.20
-Revenue (Q3): $24.14 Mln vs. $23.63 Mln last year.


Copyright(c) 2023 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX